Engineered bacteria deliver BPC-157, reducing reactive oxygen species in fibroblast cells
Background
The gastric stable pentadecapeptide BPC-157 shows promise in treating gastrointestinal inflammation by mitigating oxidative stress. A key challenge is effective delivery of therapeutic peptides to mucosal surfaces. Current methods can suffer from degradation or poor bioavailability. Lactic acid bacteria (LAB) like Lactococcus lactis are being explored as living vectors for this purpose. They can be engineered to produce and deliver therapeutic agents directly at the site of inflammation, potentially offering a more targeted and sustained release. This approach could overcome delivery hurdles for peptides like BPC-157, which reduces reactive oxygen species (ROS) production, a key factor in inflammatory damage.
Study Design
This in vitro study engineered the lactic acid bacterium Lactococcus lactis to deliver BPC-157 via two strategies: surface display and secretion. For surface display, BPC-157 was fused to either the BmpA protein or an AcmA/Usp45 fusion protein. For secretion, the Usp45 secretion signal was used. The amount of BPC-157 delivered was quantified using anti-BPC-157 antibodies and mass spectrometry. The biological activity of the secreted peptide was assessed by measuring its effect on reactive oxygen species (ROS) production in a 149BR fibroblast cell model.
Results
The secretion-based delivery method proved most effective. While the BmpA-fusion protein showed higher expression levels, the AcmA/Usp45 system resulted in a 14-fold higher surface display ability for BPC-157. However, the concentration of BPC-157 delivered via this surface display method was only 30 ng/ml. In contrast, direct secretion into the growth medium using the Usp45 signal peptide yielded a significantly higher concentration.
The
Usp45signal-mediated secretion strategy was the most effective approach, delivering a concentration of 117 ng/ml of BPC-157. Crucially, this secreted BPC-157 demonstrated biological activity by significantly decreasing reactive oxygen species (ROS) production in the fibroblast cell model, confirming its antioxidant potential in a cellular context.
Key Findings
- Usp45 signal-mediated secretion yielded the highest BPC-157 concentration at 117 ng/ml.
- Surface display via the AcmA/Usp45 fusion protein delivered a BPC-157 concentration of 30 ng/ml.
- The AcmA/Usp45 fusion protein had a 14-fold higher surface display ability for BPC-157 compared to the BmpA fusion.
- Secreted BPC-157 significantly decreased reactive oxygen species (ROS) production in a 149BR fibroblast cell model.
Why It Matters
This study establishes a proof-of-concept for using engineered probiotics as a novel delivery system for BPC-157. For individuals exploring gut health protocols, this points toward a future where a probiotic supplement could continuously produce and deliver therapeutic peptides directly to the intestinal lining, potentially offering more consistent and localized effects than periodic injections. The key takeaway is the potential for oral, self-manufacturing peptide delivery systems for gut inflammation. However, this is early-stage in vitro research. The stability, efficacy, and safety of these engineered bacteria in a live animal or human gut microbiome remain completely unproven. Extensive preclinical and clinical trials would be required before this could be considered a viable therapeutic strategy.
TitrateLab articles covering BPC-157
Written by TitrateLab, separately from the study summarized above.
